CPP
GILD icon

Crow Point Partners’s Gilead Sciences GILD Stock Holding History

Crow Point Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,029
Closed -$74K – 294
2016
Q4 		$74K Sell
1,029
-1,855
-64% -$138K 0.01% 177
2016
Q3 		$225K Buy
+2,884
New +$234K 0.04% 148
2015
Q3 		$386K Buy
+3,930
New +$436K 0.06% 128

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crow Point Partners's GILD Position: Q1 2017 in Review

Crow Point Partners sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 1,029 shares — an estimated $74K sold.

Crow Point Partners first reported a position in GILD in Q3 2015 and held it in 3 quarters. The position peaked at $386K in Q3 2015. 1,524 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Crow Point Partners reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Crow Point Partners sold 1,029 Gilead Sciences shares in Q1 2017, an estimated $74K.
  • Crow Point Partners first reported a position in Gilead Sciences in Q3 2015 and held it in 3 quarters.
  • Crow Point Partners's Gilead Sciences position peaked at $386K in Q3 2015.
  • 1,524 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Crow Point Partners's 13F filing for Q1 2017, filed 15 May 2017.